Valuation
- Market cap
- 1,709,427,000
- Revenue TTM
- $655,350,000
- Net income TTM
- $-136,230,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -20.79%
- Debt to equity
- 0.58
Trading
- Volume
- 1,166,246
- Avg volume
- 1,355,434
- Day's range
- $14.20 – $14.90
- Shares out
- 116,446,000
- Stochastic %K
- 39%
- Beta
- 0.99
- Analysts
- Sell
- Price target
- $26.86
Company profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metas...
Show more
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
- Industry
- Medical Devices
- Sector
- Healthcare
- Website
- https://www.novocure.com
- Address
- Neuhofstrasse 21, Baar, Switzerland
Latest news
No headlines yet.
Stocktwits
Tdorsey1776
Oct 21, 1:49 PM
$NVCR Back above 200 DMAV; time to grind higher as we await upcoming catalysts. Cover
2 replies
Tdorsey1776
Oct 17, 5:41 PM
$VRDN $NVCR $CADL This is the bio cycle; when you feel like puking....grab a buy ticket.
0 replies
Merlintrader
Oct 16, 11:37 AM
$NVCR Latest company news, October 1, 2026: Japan's MHLW approved Novocure's Optune Pax for unresectable locally advanced pancreatic cancer, alongside gemcitabine and nab-paclitaxel.
$NVCR reports Q3 results on October 29 before the open. Full hub (Optune markets, TRIDENT and METIS data, cash and debt): https://www.merlintrader.com/novocure-nvcr-stock-hub/ Not investment advice.
0 replies
